Acumen Pharmaceuticals Inc
acumenpharm.comWhat Do They Do?
Develops antibody treatments targeting soluble amyloid-beta oligomers for people with early Alzheimer’s disease, including sabirnetug and a brain-penetrating program with JCR.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Oct 26, 2026
−$25.4MView ↗
- ▼ −4% (Loss)
- vs −$26.5M in Q3 FY2025
-
Jun 16, 2026
Exercises option to license two brain-delivery drug candidates
The candidates combine Acumen’s antibody expertise with JCR’s blood-brain barrier technology.
Sources
8-K, filed Jun 16, 2026
On June 16, 2026, the Company announced the nomination of two EBD development candidates for the treatment of AD pursuant to its…View ↗
Who Do They Compete With?
Competes with AbbVie, Alector, Alnylam Pharmaceuticals, AltPep, Alzheon, Alzinova, BioArctic, Biogen, Bristol-Myers Squibb, Cognition Therapeutics, Denali, Eisai, Eli Lilly, Grifols, Korsana Biosciences, Neurimmune, Priavoid, ProMIS Neurosciences, Prothena Biosciences, and Roche
10-K for FY2025, filed Mar 26, 2026Other companies known to be developing therapies with Aß-, AßO- and amyloid plaque-related targets include AbbVie Inc., or Abbvie, Alector…View ↗
Loading...
